Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates
New composition of matter claims establish intellectual property for Enveric’s EVM301 Series of novel small molecules designed to promote neuroplasticity without inducing hallucinations. CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB)…
Details